Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

The effect of inhaled corticosteroids on the development of emphysema in smokers assessed by annual computed tomography

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association Between Chronic Obstructive Pulmonary Disease and Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Variants of the ADRB2 Gene in COPD: Systematic Review and Meta-Analyses of Disease Risk and Treatment Response

    Research output: Contribution to journalReviewResearchpeer-review

  3. COPD: Mortality and Readmissions in Relation to Number of Admissions with Noninvasive Ventilation

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Personality Traits and Mental Symptoms are Associated with Impact of Chronic Obstructive Pulmonary Disease on Patients' Daily life

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. The Danish severe asthma register: an electronic platform for severe asthma management and research

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The objective was to evaluate the effect of inhaled corticosteroids on disease progression in smokers with moderate to severe chronic obstructive pulmonary disease (COPD), as assessed by annual computed tomography (CT) using lung density (LD) measurements. Two hundred and fifty-four current smokers with COPD were randomised to treatment with either an inhaled corticosteroids (ICS), budesonide 400 microg bid, or placebo. COPD was defined as FEV(1) < or = 70% pred, FEV(1)/FVC < or = 60% and no reversibility to beta(2)-agonists and oral corticosteroids. The patients were followed for 2-4 years with biannual spirometry and annual CT and comprehensive lung function tests (LFT). CT images were analysed using Pulmo-CMS software. LD was derived from a pixel-density histogram of the whole lung as the 15th percentile density (PD15) and the relative area of emphysema at a threshold of -910 Hounsfield units (RA-910), and both were volume-adjusted to predicted total lung capacity. At baseline, mean age was 64 years and 64 years; mean number of pack-years was 56 and 56; mean FEV(1) was 1.53 L (51% pred) and 1.53 L (53% pred); mean PD15 was 103 g/L and 104 g/L; and mean RA-910 was 14% and 13%, respectively, for the budesonide and placebo groups. The annual fall in PD15 was -1.12 g/L in the budesonide group and -1.81 g/L in the placebo group (p = 0.09); the annual increase in RA-910 was 0.4% in the budesonide group and 1.1% in the placebo group (p = 0.02). There was no difference in annual decline in FEV(1) between ICS (-54 mL) and placebo (-56 mL) (p = 0.89). Long-term budesonide inhalation shows a non-significant trend towards reducing the progression of emphysema as determined by the CT-derived 15th percentile lung density from annual CT scans in current smokers with moderate to severe COPD.
Original languageEnglish
JournalCOPD
Volume6
Issue number2
Pages (from-to)104-11
Number of pages7
DOIs
Publication statusPublished - 2009

    Research areas

  • Administration, Inhalation, Aged, Aged, 80 and over, Budesonide, Double-Blind Method, Female, Forced Expiratory Volume, Glucocorticoids, Humans, Lung Volume Measurements, Male, Middle Aged, Pulmonary Emphysema, Smoking, Tomography, X-Ray Computed, Treatment Outcome

ID: 32555850